The Challenges of Trying to Reduce Risk In Development
To expedite the development plan, many companies choose to stick with an IV therapy they’ve used before, because it’s tried and tested. But this doesn’t align with patient preferences. Meanwhile, your competition is marketing SC injection with syringes. While SC injection with syringes is closer to the mark when it comes to patient preference, it ultimately falls short, in part because it may still require a healthcare provider to administer the medication to the patient in a clinical setting.
What is the risk of this approach?
1. Based on FDA data from the Centre for Drug/Biologic Evaluation and Research.
3. IMS Smart. US, UK, France, Germany, Italy and Spain. As of 30 June 2019; no IMS data for 2019.
4. Patients' Preferences for Subcutaneous Trastuzumab versus Conventional Intravenous Infusion for the Adjuvant Treatment of HER2- Positive Early Breast Cancer: Final Analysis of 488 Patients in the International, Randomized, Two-Cohort Prefer Study, Annals of Oncology, 2014.
West and the Diamond logo is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. © Copyright 2020 West Pharmaceutical Services, Inc.